OCTOBER-NOVEMBER-2016

VOLUME 1

ISSN-2456-4354

ISSUE 2





INTERNATIONAL JOURNAL OF AYURVEDIC RESEARCH

"IMPACT OF BHAVANA SAMSKARA ON THERAPEAUTIC EFFECT WITH SPECIAL REFERENCE TO KASISA PURIFIED BY DIFFERENT BHAVANA DRAVYAS AND THEIR EFFECT IN HAEMOGLOBIN LEVEL - A COMPARATIVE STUDY"

P Pooja ¹, K.Unnikrishna Pillai², N V Ramesh ³

¹Final year P.G Scholar, Dept. of Rasashastra and Bhaishajya Kalpana, Amrita School of Ayurveda, Kerala. ²Professor and H.O.D., Dept. of Rasashastra and Bhaishajya Kalpana, Amrita School of Ayurveda, Kerala. ³Professor, Dept. of Rasashastra and Bhaishajya Kalpana, Amrita School of Ayurveda, Kerala.

ABSTRACT

Purpose: Our *Acarays* have mentioned more than one *Sodhana Dravya* for most of the Sodhya Dravyas. Kasisa is an ideal drug to study the effect of Bhavana Dravya, as there are different Bhavana Dravyas mentioned for Kasisa Sodhana and Kasisa can be used with out *Marana*. The potential of *Bhavana Dravya* may get significantly reduced after Marana. Kasisa is remarked as a proven Rasa Dravya used in Pandu Roga. Method: To evaluate the comparitive efficacy in Pandu Roga, clinical study has been undertaken. This study incorporate an openlabel comparative clinical study on 60 diagnosed case of low haemoglobin level of age 06-15 years. Group A and group B(20 patients each) were treated with Bhirngaraja Swarasa and Nimbu Swarasa Bhavita Kasisa respectively while the group C was given the standard drug Ferrous Sulphate tablet. **Results**: On clinical study there is stastistically significant difference (p=0.038) in overall Symptom score between three groups after treatment(p<0.05). Mean change in symptom score was highest in group A(3.55=39.6% relief). In Group C it is 3.40 (31.91% reilef)and in Group B it is 2.30(29.68% relief). The mean value of change in Hb% in Group A, Group B and Group is 1.86(19.89%), 1.74(18.57%) and 1.44(15.34%) respectively. **Conclusion:** Considering the improvement in Hb% and overall effect in symptoms Bhringaraja Soditha Kasisa is proved to be better than other groups.

Key words: Bhavana, *Kasisa*, Bhringaraj Nimbu etc.

INTRODUCTION

Samskara is the processing by which some natural Gunas of the

Dravya changes and some *Gunas* are added to the *Dravyas*. Our *Acaryas* have mentioned more than one

Sodhana Dravya for most of the Sodhya Dravyas. In the present study, the influence of different Bhavana Dravyas on therapeutic potential of Kasisa is highlighted. Total outcome of Bhavan¹ depends on number of factors like Bhavana Dravya, Bhavya Dravya, Bhavana Vidhi, number and duration of Bhavana and Subhavita Laksana.

Kasisa is an ideal drug to study the effect of Bhavana Dravyas, as there are different Bhavana Dravyas mentioned for Kasisa Sodhana and Kasisa can be used with out Marana, by that we can access the effect of Bhavana Dravyas. If we are doing Marana, the property of Bhavana Dravyas may not be clearly understood as the potential of Bhavana Dravya may get significantly reduced after Marana.

According to W.H.O., anaemia is one of the conditions among the top ten selected risks to the health. Globally, anaemia affects 1.62 billion which corresponds to 24.8% of the population. 25.4% prevalence is there in school going age. So, *Pandu Roga*, has been selected for the clinical trial.

MATERIALS AND METHODS COLLECTION AND AUTHENTICATION OF RAW DRUGS.

Eclipta alba Hassk^{2,3} , Citrus limon(Linn.)Burm. F^{4,5} and Kasisa(Ferrous sulphate) were collected from the local market of Kerala and identified.

METHOD OF PREPARATION OF TRIAL DRUG.⁶

Two batches of *Kasisa*, each batch weighing 500mg was subjected to 7 bhavana with Bhringaraja Swarasa and Jambira Nimbu Swarasa separately. The dried Kasisa was again powdered and weighed. Added equal quantity of IP grade talcum powder and was passed through sieve no 60-80 to obtain a homogeneous blend and packed manually in 320mg hard gellatin capsule.

CLINICAL STUDY STUDY DESIGN

This is an openlabel , single arm, randomized, efficacy study to evaluate different bhavana dravya in *Kasisa* Shodhana.

SELECTION OF PATIENT.

All patient fullfilling the inclusion criteria were selected from medical camp irrespective of caste, relegion and economic status with written consent.

INCLUSION CRITERIA.

- Children between 6 -15 years of age, irrespective of sex, socio-economic status.
- Patients with hemoglobin percentage
 11gm/dL and below.

EXCLUSION CRITERIA:

- Children under any specific medication will be excluded.
- Children having any congenital deformity and prolonged illness will be excluded.
- Patients having Hb% below be excluded.
- Girls who attained menarche will be excluded.

GROUPING AND TREATMENT

60 patients were divided randomly into 3 groups, each containing 20 patients. Group A and group B were treated with *Bhirngaraja Swarasa Bhavita Kasisa* and *Nimbu Swarasa Bhavita Kasisa* respectively while group

C was given the standard drug Ferrous Sulphate tablet.

The study was cleared by the institutional ethics committee. Written consent was taken from the parent or guardian of each patient willing to participate before the start of the study. Treatment schedule was continued for 42 days.

ASSESSMENT PARAMETERS BEFORE AND AFTER TREATMENT

- 1. Laboratory Parameters Haemoglobin Percentage.
- 2. The predominant signs and symptoms of Pāndu like *Hrdayaspandana*, *Srama*, *Śhwāsa*, *Daurbalya* and *Pāṇduta*.

Stastistical Analysis

The efficacy of the drugs were determined from a statistical analysis of the pre and post treatment symptom scorings. (Paired -t test). For compairing the subjective parameters between groups- Chi Square test is used. For compairing the effect on Haemoglobin between groups and over all assesment – ANOVA is used.

OBSERVATION

Preparation Of *Bhringaraja* **Swarasa.** 3.5 liter of *Bhringaraja Swarasa* was obtained from 5.5 kg of fresh *Bhringaraja Pancanga* (without *Moola*). Thus yield of *Swarasa* was 63.63%.

Preparation Of Jambira Swarasa.

3.5 liter of *Jambira Swarasa* was obtained from of 9 kg of fresh *Jambira*. Thus yield of *Swarasa* was 38.8%.

RESULTS

Effect Of Therapy Based On Assessement Criteria.

Table: 1-Showing Comparision Of Change In *Panduta* In Group A, B And C. (Chi Square test)

		10.11	9441	cesty					
		TH	Gr						
Cha <mark>nge in <i>Pandu</i> BT-AT</mark>	1	A		В		С	X ²	Df	P
	N	%	N	%	N	%			
No change	1	5	10	50	2	10	21.831	6	0.001
Mild improvement	16	80	10	50	14	70	1.00		
Moderate improvement	2	10	0	0	0	0			
Good improvement	1	5	0	0	4	20	10 Per		
Total	20	100	20	100	20	100	Service Transcription		

Table: 2-Comparision of change in Swasa in Group A, B and C. (BT-AT) .(Chi Square test)

Change in <i>Swasa</i> (BT-AT)			Gr		4				
		Α		В		С	χ ²	Df	P
	N	%	N	%	N	%	/ 🔊		3
No change	11	55	13	65	9	45	1.616	2	<mark>0.446</mark>
Mild improvement	9	45	7	35	11	55			7
Total	20	100	20	100	20	100	3	H (g)	

Table: 3-Comparision Of Change In Srama In Group A, B And C. (Chi Square test)

Change in <i>Srama</i> BT-AT		V/1	Gı	A.					
		A		△ B △ B		C	X ²	Df	P
		%	N	%	N	%			
No change	9	45	8	40	10	50	0.404	2	0.817
Mild improvement	11	55	12	60	10	50			
Total	20	100	20	100	20	100			

Table : 4- Comparision Of Change In *Dourbalya* **In Group A, B And C. (**Chi Square test**)**

Change in <i>Dourbalya</i> (BT-AT)			Gre	_					
		Α		В		С	χ²	df	P
(DI-AI)	N	%	N	%	N	%			
No change	8	40	11	55	11	55	2.876	4	0.579
Mild improvement	11	55	9	45	9	45			
Moderate improvement	1	5	0	0	0	0			
Total	20	100	20	100	20	100	200		

Table:5-Comparision Of Change In Palpitation(Hridaya Spandana) In Group

A, B And C (Chi Square test)

Change in Palpitation (BT-AT)		_	Gr						
		Α		В		C	χ²	df	P
(BI-AI)	N	%	N	%	N	%			
No change	7	35	13	65	8	40	4.352	4	0.360
Mild improvement	12	60	6	30	11	55			
Moderate improvement	1	5	1	5	1	5			
Total	20	100	20	100	20	100	100		

Table:6-Comparision Of Change In Hb% In Group A, B And C.

	N	Change in I	lb% BT- AT	ANOVA		
1000		Mean	Sd	F	P	
Group A	20	1.86	0.48	2.181	.122	
Group B	20	1.74	0.78			
Group C	20	1.44	0.65		441	

Table:7-Showing Comparision Of Overall Symptom Score (BT-AT) In Three Groups.

			A		
		Change in Sym	ANOVA		
	N	Mean	△ Sd	F	P
Group A	20	3.50	1.64	3.453	.038
Group B	20	2.30	1.42		
Group C	20	3.0	1.82		

difference between the three groups after treatment in Hb%.

DISCUSSION

Haemoglobin

The mean value of change in Hb% in Group A, Group B and Group C is 1.86, 1.74 and 1.44 respectively. There is stastistically no significant

Pāṇduta:

Varṇa and Prabha are the properties of Raktadhātu and Pitta Dōṣa, particularly the Bhrājaka and Ranjaka Pitta. It is also the property of Ōjas as

more and more *Ōjakṣaya*, *Raktakṣaya* and *Pitta prakōpa* occurs the patients becomes *Hataprabha* or *Pāṇduta* appears.

Daurbalyata:

Daurbalya may due to be Dhātuksaya, Ōjaksaya as well Raktālpata which causes the debility to do any thing. If we consider it from Modern point of view the cells in the Blood are responsible for supplying oxygen to body tissues. The oxygen is very necessary for the normal metabolic activities. When there is condition is decrease in number of RBCs, metabolic activities hastened and if this condition persists for a long period, debility appears.

Hridayaspandanam

Hridayaspandanam or Palpitation in Pāṇdu Rōga is due to lack of proper nourishment and Raktālpata due to which heart has to pump quickly so as to provide rapid blood flow to body tissues. The reason for good result in all the groups may be given as the, Hb levels are increased due to Raktavardhaka properties of these

compounds, so oxygen carrying capacity of RBCs is increased and heart does not need to pump so quickly any more.

Śwāsa :

Dyspnoea on exertion or Śwāsa in Pāṇdu Rōga is due to lack of proper nourishment and Raktālpata due to which lungs have to work quickly so as to provide rapid blood flow to body tissues.

Srama

The % relief in *Srama* from Group A, B and C was 31.43%, 28.57% and 29.41% respectively and was highly significant. There is stastistically no significant difference between the three groups after treatment in *Srama*. The maximum number of patients with mild improvement in *Srama* was found in group B(60%).

Over All Symptom Score

There is stastistically significant difference (p=0.038) in overall Symptom score between three groups after treatment(p<0.05). Mean change in symptom score was highest in group A(3.50). In Group C it is 3.45 and in Group B it is 2.30.

Mode of action of the drugs.

Kasisa contains iron as well as trace elements. Bhringaraja having Balya action and it is indicated in Pandu Roga. Bhringaraja is hepatoprotective and thereby it can act at Kostagni level. Bhringaraja can correct liver metabolism which normalizes the absorption and metabolism inturn cures anaemia. At the same time hepatoprotective nature of Bhringaraja can reduce RBC distruction and liver failure related anaemia. The drugs which act in liver is also effective in Dhatwagni level.

Nimbu Swarasa acts as catalyst for the absorption of Iron at the Dhatwagni level and so, it exhibits better response in improvement of general symptoms. Nimbu can provide an acidic environment and thereby promoting iron absorption. Vitamin C and gastric intrinsic factor also play an important factor in iron absorption Alkalinity is an inhibitory factor in iron absorption. In iron deficiency state, iron store depletion refers to an imbalance between normal physiological demand and the level of dietary iron intake. And

in this state absorption of dietary iron is increased through Supplement of oral iron preparations which causes increase in iron absorption leading to synthesis of haemoglobin.

CONCLUSION

Analitical study reveals that *Sodhana Dravya* can influence the physico-chemical properties. Bhringaraja *Swarasa Śōdhita Kāsīsa* group shows, better results as compared to Jambera Swarasa Śōdhita Kāsīsa and Ferrous Sulphate tablet, both in subjective and objective parameters. Improvement in Hb% was more in Jambera Swarasa Śōdhita Kāsīsa than Ferrous Suphate tablet. No observable side effects were noted in all the three groups.Herbal ingredients present in the Sodhana *Dravya* play an important role increasing the bioavailability of iron.Based on the results of research work it may be concluded that, we can select the Sodhana Dravya depending on the disease condition.

ACKNOWLEDGMENTS.

1.Amrita School of Ayurveda, Clappana P O, Kollam, Kerala.

REFERENCES

- 1. Patil Usha.International Journal Of Ayurvedic & Herbal Medicine 6(1) Jan.-Feb2016(2075-2081) Journal Homepage: ISSN:2249-5746
- 2. Medicinal Plants of India; Vol. I, 1976, Indian Council of Medicinal
- 3. Dr.J. L. N. Shastri, Dravya Guna Vijnana (Study of Essential Medicinal plants in Ayurveda), 2nd edition, Varanasi, Chaukhambha Orientalia, II volume, 294-297 Pp

- 4.P. V. Sharma (1994) : Dravyaguna Vigyana, 15th edition Chaukhambha Surbharati Academy, Varanasi.
- 5.Dr.J. L. N. Shastri, Dravya Guna Vijnana (Study of Essential Medicinal plants in Ayurveda), 2nd edition, Varanasi, Chaukhambha Orientalia, I Volume, 105-107 Pp
- 6.Acharya Sadanada Sharma, Rasa Tarangini, Translated by Shri Kashinatha Shastri, 11th Edition.

CORRESPONDING AUTHOR

Dr Pooja P

Final Year P G Scholar Amrita School Of Ayurveda Kerala poojamelel@gmail.com

Source of Support: NIL

Conflict of Interest: None declared